← Browse by Condition
Medical Condition
t lymphoblastic lymphoma
Total Trials
2
Recruiting Now
2
Trial Phases
Phase 1, Phase 2, EARLY_Phase 1
Lymphoma trials span diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, Hodgkin lymphoma, mantle cell lymphoma, and T-cell lymphomas — each with distinct biology and treatment response. CAR-T cell therapy has established a new standard in relapsed/refractory DLBCL, and trials now aim to move this approach earlier in the treatment sequence.
Active trials evaluate bispecific antibodies (mosunetuzumab, epcoritamab, glofitamab), next-generation CAR-T cell products (CD19/CD22 dual targets, BCMA-targeting), BTK inhibitors in B-cell lymphomas, and total metabolic volume on PET as a predictive biomarker for treatment adaptation.
Trial Phases
Phase 1 2
Phase 2 1
Top Sponsors
1 trial
1 trial
NCT04315324 Phase 1, Phase 2
Recruiting
Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)
Enrollment
67 pts
Location
United States
Sponsor
SWOG Cancer Research Network
NCT06633341 EARLY_Phase 1
Recruiting
Targeting CD5 CAR-T Cells in the Treatment of r/r CD5+ T-lymphoma
Enrollment
30 pts
Location
China
Sponsor
Zhejiang University
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology